Introduction
Welcome to our new series where we share insights from clinical trials we’ve supported, highlighting what worked, what didn’t, and how we refine our patient engagement strategies. This month, we’re taking a closer look at a recent Fuchs’ Dystrophy study.
Early on, we launched our initial recruitment with traditional messaging about “new investigational treatment,” “access to expert care,” and “advancing research.” While these themes typically resonate with many patient populations, it quickly became apparent that for this study, patients had a different, and very urgent, concern: the hefty price tag associated with the standard-of-care surgery.
After hearing patients’ stories and experiences, our strategy shifted. We realized that simply informing people about investigational options and expert care wasn’t enough; what really mattered was cost. By pivoting our marketing strategy to focus on addressing out-of-pocket expenses, we opened the door to a new pool of highly motivated participants. We want to share how we discovered pain points, adapted our recruitment strategy, and dramatically boosted study enrollment for that Fuchs’ Dystrophy study.
Understanding Fuchs’ Dystrophy and the Cost Barrier
Fuchs’ Dystrophy is a progressive eye disease that affects the cornea, leading to vision impairment over time. One of the most common treatments involves corneal transplant surgery or advanced procedures to restore clearer vision. However, this surgery can be prohibitively expensive for many patients, sometimes costing thousands of dollars.
When we initially began developing our social media and digital outreach strategies for this clinical trial, our messages focused on:
- New Investigational Research – Emphasizing how participating in a clinical study could provide early access to a new investigational treatment.
- Access to Expert Care – Highlighting the specialized clinicians and research teams involved in the trial.
- Advancing Research – Reminding patients that by joining a clinical trial, they could help drive medical progress that benefits the broader Fuchs’ community.
At first glance, these messages seemed comprehensive and aligned with common motivations for clinical research participation. Yet, the patients we talked to consistently mentioned a different driver: the price of surgery. They voiced worries about high co-pays or total out-of-pocket costs. Some were delaying or outright avoiding treatment due to financial constraints.
The Patient Feedback That Sparked a Pivot
During phone calls, prescreeners, and follow-ups, we noticed a recurring theme:
“I know I need the surgery, but I just can’t afford it right now.”
That single sentiment underscored the real barrier Fuchs’ Dystrophy patients were facing. While the promise of participating in a clinical trial is often appealing in its own right—especially when discussing a serious eye condition—many of these patients were stuck worrying about cost first and foremost.
Our initial ads, which leaned heavily on general “new investigational treatment” and “expert care” messaging, didn’t fully resonate with individuals who were making financial decisions on a daily basis. They simply wanted a more affordable solution. Thankfully, this Fuchs’ Dystrophy study had an enormous benefit: participants could receive surgery and follow-up care at little or no cost.
Once we learned how critical cost concerns were, we quickly moved to obtain Institutional Review Board (IRB) approval for updated materials that clearly stated the study offered surgery at minimal or no cost to patients. This was a game-changer; now we had a direct answer to the number-one barrier patients faced.
Shifting to Search: Where Patients Actually Look for Answers
We’ve long known that when patients have very specific questions—like how to pay for an expensive surgery—they typically turn to search engines. Armed with our new insights, we realized social media ads alone might not capture those individuals urgently looking for cost relief.
- Keyword Research: We brainstormed and researched real-world search queries related to Fuchs’ Dystrophy, especially around cost. Examples included “cost of corneal transplant,” “Fuchs’ Dystrophy surgery cost,” “affordable eye surgery,” and “Fuchs’ transplant financial assistance.”
- Google and Partner Sites: We set up targeted campaigns on Google that addressed those specific pain points, along with partner sites within Google’s display network. This allowed us to display relevant ads to people actively researching cost-related topics.
- Cost-Focused Ad Messaging: Each ad mentioned that this particular study might provide little-to-no-cost surgery for qualified participants. We still mentioned the investigational nature of the research and expert care, but the core headline and hook directly tackled cost.
The Results: 66% of Site-Assigned Patients Came from Search
This pivot toward cost-focused messaging and targeted search engine ads delivered impressive results. Over the course of the recruitment period:
- Search Channels Became the Leading Driver: Nearly 66% of all the patients we assigned to study sites came through search engines (primarily Google) and Google’s partner network.
- Higher Conversion Rates: Because we were answering a pressing question—“How can I afford Fuchs’ surgery?”—patients who clicked these ads were more likely to complete the prescreener and follow through.
- Reduced Prescreener Drop-Offs: The mention of little-to-no-cost surgery in the ad copy cleared up the biggest patient hesitation early on. This transparency kept potential participants engaged and less likely to abandon the process of seeking out the next step in their health journey.
One of the biggest benefits here was the alignment of message and need. We weren’t just promising “expert care” or “helping medical research”; we were also directly responding to the exact problem patients were trying to solve. This drastically improved both the quality and the urgency of the inquiries we received.
Lessons Learned
- Listen to the Patient First
- Our initial approach was based on a standard playbook of motivational factors for clinical trial recruitment—new research, helping science, expert care. While these remain important, they were overshadowed by the financial stress patients felt about costly surgery. Taking the time to actually hear patients’ concerns allowed us to refine messaging that matched their real-world challenges.
- Adapt and Approve
- Once we identified cost as the priority, we worked quickly to get IRB approval for materials clearly indicating the minimal or no-cost nature of the surgery. It’s crucial to adapt study materials swiftly while staying compliant with regulatory requirements.
- Meet Patients Where They’re Searching
- Social media can be great for awareness, but when a patient is ready to solve a major financial problem—like covering an expensive operation—they tend to consult search engines. Tailoring ads to match high-intent keywords proved essential.
- Highlight Practical Benefits
- While altruism and general interest in research can spark some participation, patients dealing with significant financial barriers often want concrete answers. If your study addresses those barriers (e.g., free or subsidized care), don’t bury that information. Let patients know what’s possible.
- Stay Agile
- We were able to pivot mid-campaign based on patient feedback. Being flexible allowed us to rework our strategy and achieve strong results—66% of site assignments came from this new search-based, cost-focused approach.
Taking This Approach Forward
For sponsors and site teams, the key takeaway is the power of aligning recruitment strategies with the actual, tangible concerns of the target patient population. The Fuchs’ Dystrophy study demonstrates how a seemingly small shift in messaging—centering on the high cost of surgery—can have a major impact on recruitment success.
By focusing on what truly matters to patients—particularly if it’s a cost issue—you can see dramatic improvements in qualified patient referrals. Instead of relying solely on traditional “investigational care” messages, we spoke directly to what patients were searching for: cost relief.
By meeting them at their point of need, we not only increased patient engagement but helped many individuals access a potentially life-changing opportunity at little or no cost. We explored this shift in more detail in our “Fuchs Dystrophy Explained” post, where we break down how audience-first messaging can reshape trial outreach.
At Leapcure, our monthly “Study Insights” blog series will continue to highlight similar real-world experiences and lessons learned. Each study tells a unique story: sometimes it’s about how to effectively target new symptom-related keywords, other times it’s about leveraging social communities for awareness. But in every case, the overarching goal remains the same: to refine our recruitment methods so that patients who stand to benefit most from clinical trials can find them more easily. In simple terms, to strive towards our company mission, “Impactful medical breakthroughs for everyone, with everyone.”
We look forward to sharing more stories like this as part of our monthly blog series. Also, if you think you or someone you know might have Fuchs’ Dystrophy, you can let us know here to see if there is an eligible. Let’s continue shaping clinical research recruitment around the people who need it most.
Leave a Reply